Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera raised $275 million in its IPO ... Also on Thursday, Maze Therapeutics priced an upsized IPO at $16 a share, in the middle of a marketed range, according to a statement.

Sionna is working out its IPO plans days after obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics both listed on the Nasdaq with offerings of $275 million and $140 million ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

Metsera's IPO is richest among the Friday debutantes ... of $44.1 million and revenue of $12 million for full-year 2023. Maze Therapeutics Inc. (MAZE) priced 8.75 million shares at $16 a share ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

Obesity biotech Metsera (MTSR) priced its downsized ... Precision medicine biotech Maze Therapeutics (MAZE) priced its upsized IPO at the midpoint to raise $140 million at a $731 million market ...

Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

At the closing bell, Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18. It opened on the Nasdaq at $25.50. Back To Top ...